Head-to-head · WeighScore
AbundRX vs Invigor Medical
By GLP-1 ScorecardUpdated
Score comparison
Invigor Medical has the higher recorded score — 86.1/100 to 66.6/100.
Invigor Medical grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. An established pharmacy operator with steady mid-market pricing and a broad catalog.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | AbundRX | Invigor Medical |
|---|---|---|
| WeighScore | 66.6/100 | 86.1/100 |
| Grade | C | B |
| Site position | #205 | #10 |
| Semaglutide | $179/mo (compounded) | $199/mo |
| Tirzepatide | $279/mo (compounded) | $339/mo |
| Coverage | Coverage not published | Not disclosed |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #205 · C
Strengths
- Two clear compounded GLP-1 pathways with transparent pricing — semaglutide $179/mo and tirzepatide $279/mo
- Fast, free shipping and a simple few-minute online health assessment
- Provider-guided care connecting patients with licensed US clinicians
- Publishes Terms, Privacy, and Refund policies
What to consider
- Claims LegitScript certification in text but displays no verifiable seal or listing
- Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
- Compounding pharmacy not named; no HIPAA notice found; state availability not published
- Heavily hedged marketing language ('may include', 'helping connect patients') — reads like a lead-generation platform
Site position #10 · B
Strengths
- Mid-market pricing on both molecules
- Long-running operator
What to consider
- No explicit states list
- Compounded only
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.